Literature DB >> 8857751

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.

E C Wolters1, E N Jansen, H G Tuynman-Qua, P L Bergmans.   

Abstract

We studied the effect of olanzapine (1 to 15 mg/d) in 15 nondemented parkinsonian patients with drug-induced psychosis. Psychotic symptoms decreased significantly during treatment, and there was no worsening of extrapyramidal symptoms. These results suggest that olanzapine is a well-tolerated and effective treatment for drug-induced psychosis in nondemented patients with Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8857751     DOI： 10.1212/wnl.47.4.1085

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Late-onset schizophrenia: epidemiology, diagnosis, management and outcomes.

Authors:  P A Wynn Owen; D J Castle
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 2.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 3.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 4.  Neuropsychiatric non-motor aspects of Parkinson's disease.

Authors:  B R Thanvi; S K Munshi; N Vijaykumar; T C N Lo
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

5.  Hallucinosis in idiopathic Parkinson's disease.

Authors:  J M Graham; R A Grünewald; H J Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 6.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

7.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

8.  Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care.

Authors:  Raphael J. Leo; Paula Del Regno
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

9.  Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Authors:  Prakash S. Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06

Review 10.  Treatment of psychosis in Parkinson's disease: safety considerations.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Joseph H Friedman
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.